HHS allows compounding pharmacies to produce certain peptides amidst regulatory updates.
In a recent announcement, the Department of Health and Human Services (HHS) has temporarily permitted compounding pharmacies to manufacture six specific peptides. This decision comes as the agency works on revising its rules regarding these substances.
Six Peptides Under Discussion
The peptides that have been given the green light include BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500. Although these compounds are touted online for benefits such as enhanced healing, youthful skin, and potentially extending lifespan, it's crucial to note that none have received approval from the Food and Drug Administration (FDA).
Regulatory Safety Measures
The FDA has expressed concerns regarding the safety and effectiveness of these peptides, stating that there is insufficient data available to support their claims. Under the new regulatory framework, compounding pharmacies are required to ensure the identity and purity of these peptides and must report any side effects associated with their use, which was not previously mandated.
Concerns Over the Gray Market
This measure aims to discourage the growing